Pfizer: collaboration deal with Sangamo on gene therapy
(CercleFinance.com) - Pfizer has signed a collaboration deal with Sangamo Therapeutics for the development of a gene therapy for neuro-degenerative disorders.
The two firms will work together, using zinc finger protein transcription factors, to treat amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD) linked to gene mutations.
Under the terms of the collaboration agreement, Sangamo will receive a 12 million dollar upfront payment from Pfizer.
Sangamo is also eligible to receive potential development and commercial milestone payments of up to 150 million dollars, as well as royalties on net sales, the companies said.
In May 2017, Sangamo and Pfizer already entered into an exclusive agreement for the development and marketing of potential gene therapy products for hemophilia.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
The two firms will work together, using zinc finger protein transcription factors, to treat amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD) linked to gene mutations.
Under the terms of the collaboration agreement, Sangamo will receive a 12 million dollar upfront payment from Pfizer.
Sangamo is also eligible to receive potential development and commercial milestone payments of up to 150 million dollars, as well as royalties on net sales, the companies said.
In May 2017, Sangamo and Pfizer already entered into an exclusive agreement for the development and marketing of potential gene therapy products for hemophilia.
Copyright (c) 2018 CercleFinance.com. All rights reserved.